Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (461)	10/18/2001 9:35:27 AM
From: tuck	Read Replies (1) \| Respond to of 1005

>>HOUSTON and AUSTIN, Texas, Oct. 18 /PRNewswire/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - news) announced today that an abstract describing a preclinical study using its product candidate INGN 251, Adenoviral-PTEN, to inhibit the growth of vascular smooth muscle cells was published in Circulation, the journal of the American Heart Association. The studies showed that treatment with INGN 251 inhibited the growth of animal smooth muscle cells by as much as 70 percent. This type of treatment could be useful to help prevent arterial blockage (restenosis) which frequently occurs following common treatments for cardiovascular disease and peripheral arterial disease, including treatments such as angioplasty, stenting and bypass grafting. This research is being conducted with The Texas Heart Institute (THI) under a collaborative arrangement between Introgen and THI. The studies were conducted at the Texas Heart Institute, the University of Texas' Houston Medical School and Introgen Therapeutics. These data will be presented next month at the annual meeting of the American Heart Association in California. This meeting is expected to be the largest international gathering of cardiovascular, cardio thoracic and vascular professionals in the world. The PTEN gene is important for diagnosis and treatment of cancer and for treatment for hyperproliferative diseases such as arterial disease and rheumatoid arthritis. Introgen is the exclusive licensee of this gene from Imperial Cancer Research Technology, Ltd. in the United Kingdom. Introgen is a leader in the development and production of gene-based drugs for the treatment of cancer and other diseases. Introgen's product candidates engage precise molecular targets to produce a highly specific therapeutic effect. By selectively killing cancer cells and harnessing natural protection mechanisms, Introgen's product candidates may be less toxic than conventional treatments. Introgen specializes in combining appropriate gene delivery systems and therapeutic genes to make its gene-based drugs. Introgen is currently conducting two Phase III clinical trials for the treatment of head and neck cancer with its lead product candidate, INGN 201. Introgen's gene therapeutics have been used in approximately twenty clinical trials worldwide either alone or in combination with conventional treatments such as chemotherapy, surgery and radiotherapy. Introgen is also conducting a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer. In addition, under the Cooperative Research and Development Agreement between Introgen and the NCI, NCI is sponsoring Phase I trials in lung, bladder, ovarian and brain cancer. New applications using the human immune system with INGN 201 are being explored. Introgen's second product candidate, INGN 241 (Adenoviral-mda7) for the treatment of solid tumors, is in Phase I clinical development.<< snip Cheers, Tuck